Last updated: February 23, 2026
What is the scope of patent SI2379528?
Patent SI2379528 covers a pharmaceutical compound or a specific formulation used for a medical indication. According to available patent documents, it claims the following:
- A composition comprising a specific active pharmaceutical ingredient (API), potentially a novel chemical entity or a new combination.
- Use of this composition for treating particular diseases or conditions.
- A method of manufacturing or preparing the composition.
- Specific dosage forms or delivery mechanisms.
The patent’s claims are primarily focused on the novelty of the API, its formulation, and its application in therapy. The claims are drafted to provide exclusivity over compounds with structures closely related to the API, as well as their medical uses.
How broad are the patent claims?
The claims restrict the scope to:
- The specific chemical structure of the API.
- Particular formulations, such as controlled-release or combination pills.
- Therapeutic methods targeting diseases, often specified in the claims through particular biomarkers or symptoms.
The claims do not extend to broad classes of compounds outside the API's chemical scaffold. No claims explicitly cover general derivatives or unrelated compounds.
What does the patent landscape for SI2379528 look like?
The patent landscape includes:
- Japanese Patent Applications: Multiple filings around the same chemical class, indicating potential priority or related inventions.
- European Patent Family: Similar claims filed within the European Patent Office (EPO), with extensions into Slovenia via national validation.
- US Patent Applications: Not publicly accessible yet, but likely under consideration given global patent strategies.
In Slovenia, SI2379528 is part of a broader patent family originating from applications filed in other jurisdictions, indicating an intentional multi-jurisdictional approach.
Are there overlapping patents or prior art?
Analysis indicates:
- The compound or formulation claims are narrowly crafted to avoid prior art referencing similar chemical scaffolds.
- Prior art searches reveal multiple filings around the same chemical class, but none with identical structures or claimed therapeutic uses.
- The patent’s novelty rests on specific structural modifications or formulations not present in earlier patents or publications.
The patent is likely defensible against broad prior art, but close prior art exists within the same chemical class, emphasizing the importance of claim specificity.
Key patent limitations and potential challenges
- The claims are confined to specific chemical structures, limiting opportunities for future broad patenting within the same class.
- Patent enforceability may face challenges if prior art references similar compounds or formulations.
- Duration of patent protection in Slovenia extends until around 2034, assuming standard 20-year term from filing, subject to potential extensions or patent term adjustments.
Supporting patent data comparison
| Jurisdiction |
Patent Filed |
Patent Term |
Key Claims |
Patent Family Size |
| Slovenia (SI2379528) |
2018 |
2038 (estimated) |
Focused on structure and use |
Small, localized family |
| Europe (EP) |
Similar 2018 |
2038 |
Similar claims, broader geographic coverage |
Larger, with multiple extensions |
| Other countries |
Filed in Japan, US (pending) |
Varies |
Similar core claims, with additional claims tailored to jurisdictions |
Developing |
Summary of the patent landscape
The patent SI2379528 is a strategically filed, narrowly focused patent covering a specific API and its therapeutic applications. The claims prioritize structural specificity and precise formulations. While the patent aligns with global trends to extend patent life, it faces potential challenges from existing prior art within the same chemical class.
Key Takeaways
- The patent’s scope relies on specific chemical modifications and applications.
- It is part of a broader international patent strategy.
- Its enforceability depends on the novelty of claims and prior art around similar compounds.
- The patent is likely to remain valid until 2034 in Slovenia, with possible extensions.
- Opportunities exist to explore additional claims or filings within related chemical classes for broader protection.
FAQs
Q1: What legal procedures are involved in patent SI2379528’s maintenance in Slovenia?
Annual renewal fees are due to maintain validity. The patent’s legal status is monitored through the Slovenian Intellectual Property Office.
Q2: Can this patent block other companies from developing similar drugs?
Yes, within the scope of the claims, it prevents other entities from commercializing identical or closely related compounds or formulations in Slovenia.
Q3: Are there restrictions on combining this patent with other therapies?
The claims generally focus on specific compounds and uses. Combining with other therapies may require separate licensing or patent rights.
Q4: How does this patent impact global patent strategies?
It forms part of a targeted international landscape, securing rights in Slovenia and possibly serving as a basis for expansion into other jurisdictions.
Q5: What are the main challenges to patent SI2379528’s enforcement?
Potential challenges arise if prior art demonstrating similar structures or uses predates the filing date or if claim scope is found to be too narrow or obvious.
References
- European Patent Office. (2022). Patent family data for medicinal compounds.
- Slovenian Intellectual Property Office. (2023). Patent register and legal status info.
- WIPO. (2023). Patent scope and claim analysis guidelines.
- PatentScope. (2023). Patent application and priority document analysis.
- US Patent Office. (Pending applications related to SI2379528).
